Today: 20 May 2026
Denison Mines stock jumps with uranium names as Phoenix approvals come into focus
16 January 2026
2 mins read

Denison Mines stock jumps with uranium names as Phoenix approvals come into focus

New York, Jan 16, 2026, 10:04 ET — Regular session

  • Denison Mines shares climbed roughly 4% in early trading, riding the broader upswing in uranium-related stocks
  • Cameco and Uranium Energy pushed higher, building on gains driven by rising optimism around nuclear fuel.
  • Traders await final approvals that would clear the way for Denison to begin construction on its Phoenix uranium mine in Canada

Denison Mines Corp shares climbed roughly 4.1% to $3.70 on Friday morning, having peaked at $3.80 earlier in the session. On the NYSE American, the stock swung between $3.58 and $3.80, with around 7.3 million shares traded.

Uranium stocks climbed, with Cameco rising around 3.8%. Uranium Energy jumped about 4.6%, while NexGen Energy picked up close to 2%.

Why this matters now: the group acts as a stand-in for uranium price bets, and investors are focusing on developers hitting permitting milestones soon. According to Sprott Physical Uranium Trust, there were 75.4 million pounds of U3O8 in inventory, valued at about $6.43 billion on Jan. 15, which works out to roughly $85 per pound.

Uranium isn’t traded on a central exchange like oil or gold; instead, most deals happen through private contracts. Cameco’s published industry-average prices put the spot price at $81.55 per pound as of Dec. 31, 2025, with the long-term price at $86.50.

Denison has been on investors’ radar since Jan. 2, when it announced readiness to make a final investment decision and begin building its Phoenix in-situ recovery (ISR) uranium mine, subject to regulatory approvals. The company outlined a two-year construction schedule and aims for first production by mid-2028, assuming approvals come through in the first quarter of 2026.

ISR, or in-situ recovery, is a mining technique that injects a solution into the underground ore body to dissolve uranium, then pumps it back to the surface for processing. This method limits surface disruption but faces intense regulatory and engineering oversight since the extraction occurs underground.

Denison has been making progress on infrastructure. On Jan. 8, it announced that Saskatchewan Power Corp’s grid supply is now connected at the future Phoenix site, thanks to a new 138-kilovolt transmission line. The company said this enables early construction activities and the planned “freeze wall” surrounding the initial mining zone. CEO David Cates described the project as “on schedule and on budget.” Denison Mines Corp.

Smaller Athabasca explorers outside the company are focusing on Denison-linked territory. Foremost Clean Energy announced Thursday it has hired RedChip Companies for investor relations. CEO Jason Barnard highlighted plans for “multiple drill programs” and an option to earn up to 70% interest in 10 promising uranium properties from Denison. GlobeNewswire

Equity traders face a straightforward scenario: Denison’s value moves with uranium sentiment but hinges heavily on a binary timeline — permits, green lights for construction, and a build schedule laid out in quarters and years.

The downside risk is sharp. Back in November, Denison revealed a judicial review application aimed at overturning Saskatchewan’s environmental assessment approval for the Wheeler River project. The claim? That the government didn’t meet its duty to consult. Denison, however, insists the consultation process was meaningful and says it will fight the challenge. Any hiccup in approvals or a weakening uranium market can quickly drag down developer stocks.

Denison’s next major hurdle is regulatory: the company is awaiting final approvals to kick off construction at Phoenix, aiming to secure them by Q1 2026. After that, focus will shift to the timing of a final investment decision and the start of early construction — all while watching if uranium prices stay supportive for the sector.

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Palantir stock slides in early trade as PLTR volatility, options expiry loom
Previous Story

Palantir stock slides in early trade as PLTR volatility, options expiry loom

Applied Materials stock rises as Barclays upgrade meets TSMC’s plan to spend up to $56 billion
Next Story

Applied Materials stock rises as Barclays upgrade meets TSMC’s plan to spend up to $56 billion

Go toTop